RGD-modified polymer and liposome nanovehicles: Recent research progress for drug delivery in cancer therapeutics
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
&NA; Over the past few decades, as the demand for cancer treatment has increased, more rational treatment options (considering size, mode of administration, biocompatibility, efficacy, etc.) and plenty of specifically active targeted nanovehicles have been developed. Integrin receptors targeting are one of the most frequently used approaches because of its highly expressed in cancer cells. In particular, the arginine‐glycine‐aspartic acid (RGD) peptide and its derivatives have been widely used as ligands for integrin to increase direct targeting capabilies. Polymers as well as liposomes are commonly used as nanovehicles for drug delivery. A variety of work is focused on the RGD‐modified polymer and liposome nanovehicles for cancer therapeutics. The goal of this article is to review the published literature in recent years concerning the RGD‐modified liposome and polymer nanovehicles to highlight its successful designs for improving cancer therapy and discuss the current challenges as well as the possible development prospects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
Polymer-based nanocarriers for vaginal drug delivery
das Neves, J., Nunes, R., Machado, A., & Sarmento, B. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.004 · Cited by 138
Cited by
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Nakhaei, P., Margiana, R., Bokov, D. O., Abdelbasset, W. K., Jadidi Kouhbanani, M. A., Varma, R. S., Marofi, F., Jarahian, M., & Beheshtkhoo, N. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.705886 · Cited by 479
RetractedAdvance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery
Almeida, B., Nag, O. K., Rogers, K. E., & Delehanty, J. B. (2020) · Molecules · doi:10.3390/molecules25235672 · Cited by 298
The Development of Functional Non-Viral Vectors for Gene Delivery
Patil, S., Gao, Y.-G., Lin, X., Li, Y., Dang, K., Tian, Y., Zhang, W.-J., Jiang, S.-F., Qadir, A., & Qian, A.-R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215491 · Cited by 263
Metadata
- Authors
- Cheng, Y., & Ji, Y.
- Venue
- European Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 128
- Pages
- 8-17
- ISSN
- 0928-0987 (ISSN-L)
- OpenAlex
- W2900494163
- Cited by
- 112
- References
- 3
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RGD-modified polymer and liposome nanovehicles: Recent research progress for drug delivery in cancer therapeutics. https://app.cochat.ai/papers/10.1016/j.ejps.2018.11.023
- The paper
- Cheng, Y., & Ji, Y. (2019). RGD-modified polymer and liposome nanovehicles: Recent research progress for drug delivery in cancer therapeutics. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2018.11.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.